Bile salt export pump (BSEP) adenosine triphosphate-binding cassette B11 (ABCB11) is a liver-specific ABC transporter that mediates canalicular bile salt excretion from hepatocytes. Human mutations in ABCB11 cause progressive familial intrahepatic cholestasis type 2. Although over 150 ABCB11 variants have been reported, our understanding of their biological consequences is limited by the lack of an experimental model that recapitulates the patient phenotypes. We applied CRISPR/Cas9-based genome editing technology to knock out abcb11b, the ortholog of human ABCB11, in zebrafish and found that these mutants died prematurely. Histological and ultrastructural analyses showed that abcb11b mutant zebrafish exhibited hepatocyte injury similar to that seen in patients with progressive familial intrahepatic cholestasis type 2. Hepatocytes of mutant zebrafish failed to excrete the fluorescently tagged bile acid that is a substrate of human BSEP. Multidrug resistance protein 1, which is thought to play a compensatory role in Abcb11 knockout mice, was mislocalized to the hepatocyte cytoplasm in abcb11b mutant zebrafish and in a patient lacking BSEP protein due to nonsense mutations in ABCB11. We discovered that BSEP deficiency induced autophagy in both human and zebrafish hepatocytes. Treatment with rapamycin restored bile acid excretion, attenuated hepatocyte damage, and extended the life span of abcb11b mutant zebrafish, correlating with the recovery of canalicular multidrug resistance protein 1 localization. Conclusions: Collectively, these data suggest a model that rapamycin rescues BSEP-deficient phenotypes by prompting alternative transporters to excrete bile salts; multidrug resistance protein 1 is a candidate for such an alternative transporter. (HEPATOLOGY 2018;67:1531-1545. B ile secretion from hepatocytes is the main route of excretion for exogenous toxic lipophilic substances, cholesterol, and bilirubin.
B
ile secretion from hepatocytes is the main route of excretion for exogenous toxic lipophilic substances, cholesterol, and bilirubin. (1) It is also required for digestion of dietary fats and fat-soluble vitamins in the intestine. The rate-limiting step in bile secretion is mediated by the bile salt export pump (BSEP) adenosine triphosphate-binding cassette B11 (ABCB11) that belongs to the ABC transporter superfamily. (2) It is selectively enriched at the apical membrane of hepatocytes to transport monovalent bile salts across the canalicular membrane. (3) Impairment of BSEP function leads to intrahepatic accumulation of Abbreviations: ABC, adenosine triphosphate-binding cassette; BODIPY, 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid; BSEP, bile salt export pump; CGamF, cholylglycylamidofluorescein; DMSO, dimethyl sulfoxide; dpf, days postfertilization; ER, endoplasmic reticulum; hpf, hours postfertilization; Mdr1, multidrug resistance protein 1; PFIC2, progressive familial intrahepatic cholestasis type 2; TEM, transmission electron microscopy; WT, wild type.
toxic bile acids. Lack of luminal bile acids also causes fat malabsorption, malnutrition, and fat-soluble vitamin deficiency.
The most severe form of BSEP deficiency, progressive familial intrahepatic cholestasis type 2 (PFIC2), is an early-onset childhood disease which progresses rapidly to end-stage liver failure and predisposes to hepatocellular carcinoma. (4) Liver transplantation remains the only effective treatment. (5) Studies to classify ABCB11 mutations based on their impact on protein expression and function have been mostly conducted in vitro and have yielded controversial results. (6) The only in vivo model, the Abcb11 knockout mouse, develops mild cholestasis. (7) (8) (9) This may result, in part, from detoxification of hydrophobic bile acids by hydroxylation in rodents. (8) Increased expression of another canalicular transporter, multidrug resistance protein 1 (MDR1), may compensate for the loss of ABCB11. (7) MDR1 transcript expression does not increase in the livers of patients with PFIC2. (10) It is not clear whether MDR1 has a compensatory role in humans with BSEP deficiency.
Because Abcb11 knockout mice do not fully recapitulate PFIC2 pathology, an additional animal model is needed. The small teleost zebrafish (Danio rerio) has gained increasing popularity in liver research. The zebrafish liver contains counterparts of mammalian liver cell types and becomes functional by 4 days postfertilization (dpf). (11) The cholangiocyte-specific and hepatocyte-specific transgenic zebrafish allows direct observation of the intrahepatic bile ducts and hepatocytes, respectively. (12) Bile flow can be tracked in live larvae following feeding with fluorescent lipid analogs. (13, 14) Zebrafish has been applied in the study of inherited cholestasis syndromes including Alagille syndrome (15) and biliary atresia. (16, 17) Although zebrafish express several canalicular transporters with high homology to the human proteins, (18) they have not been used to study bile secretion.
In the present study, we modeled BSEP deficiency using zebrafish. We detected impaired bile excretion, mislocalized Mdr1 expression, and induction of autophagy in the hepatocytes of abcb11b mutant zebrafish and a patient with nonsense mutations in ABCB11. Rapamycin partially restored bile excretion, recovered the canalicular localization of Mdr1 in zebrafish mutants, and improved their survival, suggesting strategies to treat cholestasis caused by BSEP deficiency.
Materials and Methods
Additional information can be found in the Supporting Information.
HUMAN SUBJECTS
Patient A, a Caucasian female child, presented at 7 months of age with jaundice, malnutrition, and severe pruritus and underwent percutaneous liver biopsy, when the liver tissues for the current study were obtained. At that time, serum aspartate aminotransferase, alanine aminotransferase, conjugated bilirubin, c-glutamyltransferase, and total bile acid levels were 331 IU/L, 316 IU/L, 4.1 mg/dL, 19 IU/L, and >300 lmol/L, respectively. At most recent follow-up at 8.5 years of age, the patient had survived with the native liver but showed refractory pruritus, malnutrition, and severe fat-soluble vitamin deficiency.
Patient B, an African American female child, was diagnosed in infancy with PFIC2 because of chronic cholestasis and the genetic diagnosis of BSEP disease in the biological sister whose case was reported before. (19) She rapidly progressed to liver failure with a , and abcb11b ci2001/-zebrafish were maintained under standard conditions (20) in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised 1985) and approved by the Institutional Animal Care and Use Committee at Cincinnati Children's Hospital Medical Center. Animals of both genders were studied. Detailed methods for generating abcb11b mutant and Tg(fabp10a:hBSEP-GFP) ci202 transgenic zebrafish are provided in the Supporting Information.
BODIPY AND CHOLYLGLYCYLAMIDO-FLUORESCEIN FEEDING ASSAYS
For the 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-pentanoic acid (BODIPY) assay, 6-day-old larvae were fed with 6.4 lM BODIPY C5.0 (Invitrogen, Waltham, MA) for 7 hours before being scored live for gallbladder fluorescence. (13) For the cholylglycylamidofluorescein (CGamF) assay, 6-dayold larvae were incubated in egg water containing 10 lM CGamF (gift from Dr. Alan Hofmann, University of California San Diego) (21) in the dark at room temperature with agitation for 7.25 hours. Larvae were imaged live on a Nikon A1Rsi inverted confocal microscope (Nikon Instruments Inc., Melville, NY).
STATISTICAL ANALYSIS
One-way analysis of variance and Tukey's post hoc test were performed using GraphPad Prism (GraphPad Software, La Jolla, CA). Statistical analyses of the BODIPY and CGamF feeding experiments were performed using Fisher's exact test and the Ridit test, respectively, followed by a pairwise comparison on R software (R-project, Vienna, Austria).
Results

IDENTIFICATION OF THE ZEBRAFISH ORTHOLOG OF ABCB11
ENSEMBL genome assembly predicts that zebrafish possess two co-orthologs of the human ABCB11 gene (Fig. 1A) . Zebrafish Abcb11a and Abcb11b proteins show 65% and 70% identity to human ABCB11 and are 63% and 67% identical to their mouse counterparts, respectively ( Fig. 1B; Supporting Fig. S1 ). Whole-mount in situ hybridization of WT larvae showed that abcb11a transcript was enriched in the intestine (Fig. 1C) , whereas abcb11b was specifically expressed in the liver (Fig. 1D ). Zebrafish genome contains 11 members of the Abcb gene family. By quantitative real-time PCR, we found that, in addition to abcb11b, six other Abcb genes were expressed at modest levels in the livers of 5-day-old WT larvae (Supporting Fig. S2A ). Both mammalian Abcb11 and zebrafish abcb11b genes encode full transporters with two sets of transmembrane motifs and nucleotide binding folds. (18) Among the other Abcb genes that are expressed in the larval livers, abcb4 also encodes a full transporter and is shown to be the ortholog of mammalian Abcb1. (22) abcb6b, abcb7, abcb8, abcb9, and abcb10 encode half-transporters with only one transmembrane motif and one nucleotide binding fold. (18) The similar gene expression pattern and protein sequence indicate that zebrafish abcb11b is the ortholog of mammalian Abcb11.
In mammalian liver, the bile canaliculus is located at the apical surface of adjacent hepatocytes, with its lumen sealed by tight junctions to prevent diffusion of bile acids. (23) Transmission electron microscopy (TEM) showed that the zebrafish bile canaliculus is formed on the apical side of hepatocytes and sealed by tight junctions between the intrahepatic biliary cells and hepatocytes (Fig. 1I,K) . (15, 24, 25) It was enriched with actin microvilli, similar to mammals. Using a polyclonal antibody raised against mouse ABCB11, (26) we detected Abcb11 protein in zebrafish hepatocytes at 120 hours postfertilization (hpf) (Fig. 1E-H) . High-magnification confocal imaging revealed punctate Abcb11 protein expression along the canaliculi (Fig. 1J) , similar to the expression of mammalian ABCB11. (27) 
GENERATION OF ABCB11B MUTANT ZEBRAFISH
To determine whether zebrafish Abcb11b has a similar function as mammalian ABCB11, we knocked out abcb11b in zebrafish using CRISPR/Cas9-mediated genome editing technology. (28) We targeted the eighth exon of the abcb11b gene and obtained the abcb11b ci200 allele with a 1-bp deletion, a 3-bp insertion, and a T to A nucleotide change. The mutation resulted in frameshift and premature stop codon ( Fig. 2A) . The mutant protein is predicted to retain only the first transmembrane helix and the first extracellular loop but to lack the remaining 11 transmembrane helices and both nucleotide binding folds (Fig. 2B) . The mutation caused reduced abcb11b transcript expression and an absence of Abcb11b protein ( Fig. 2C-J transcript expression in the abcb11b mutant liver by in situ hybridization (Supporting Fig. S2D ,E).
ABCB11B MUTANT ZEBRAFISH EXHIBITED HEPATOCELLULAR INJURY SIMILAR TO THAT OBSERVED IN PATIENTS WITH PFIC2
We raised the embryos from abcb11b 1/-incrosses and started to observe mutant death at 11 dpf (Supporting Fig. S3A ). Of the 54 fish that survived to adulthood, there were 19 WT and 33 heterozygotes but only two mutants (2/54 5 3.7%), confirming that the abcb11b mutation was lethal. At 11 dpf, the mutant fish were shorter than the WT and heterozygous siblings and had enlarged livers (Supporting Fig. S3B ,C). Hematoxylin and eosin staining revealed hepatocyte swelling and necrosis (Fig. 3B , red box and arrow, respectively) and disorganized intestinal epithelium with increased apoptosis (Supporting Fig. S3D-F) . Quantitative real-time PCR analyses showed that the expression levels of hepatic function genes were drastically decreased in the abcb11b mutant livers at 10 dpf, right before they started dying (Supporting Fig. S3G ). This result indicates that liver function is severely compromised in abcb11b mutants.
To compare the liver phenotypes in abcb11b mutant zebrafish with human PFIC2, we performed histological analyses on liver tissues from control and two patients with PFIC2. Patient A carries two heterozygous pathogenic variants, c.1408C>T(p.R470*) and c.3945delC(p.T1316Lfs*64), in the ABCB11 gene.
The c.1408C>T variant is a previously reported nonsense mutation that abolishes ABCB11 protein expression. (29, 30) The c.3945delC variant is predicted to cause frameshift that eliminates the stop codon and extends the open reading frame of the mutant allele for 57 extra amino acids. The resulting mutant protein is predicted to preserve all of the transmembrane and nucleotide binding domains. Hematoxylin and eosin (N,O) TEM images of the bile canaliculi in WT and abcb11b mutant zebrafish at 6 dpf. Red arrows in (O) point to amorphous bilelike deposits near the bile canaliculus. (P) Length and width (mean 6 SEM) of the bile canaliculi in 5 dpf zebrafish. Measurements were performed on the confocal three-dimensional projections of six WT, six heterozygous, and six mutant larvae stained with phalloidin to mark the canaliculi. Statistical significance was calculated by one-way analysis of variance and Tukey's post hoc test. ****P < 0.0001. Scale bars, (A,B) 20 lm, (C-E) 50 lm, (F-K) 2 lm, (insets) 500 nm, (L-O) 1 lm. Abbreviation: n, nucleus. staining revealed normal liver architecture, minimal inflammation, patchy giant cell transformation (Fig.  3D) , zone 3 pericellular fibrosis, and mild periportal fibrosis (data not shown). Patient B carries two heterozygous pathogenic variants, c.2782C>T(p.R928*) and c.3268C>T(p.R1090*), in the ABCB11 gene. Both variants were nonsense mutations causing an absence of ABCB11 protein. (19) Hematoxylin and eosin staining revealed a severely distorted lobular structure with prominent giant cells surrounded by fibrous tissue (Fig. 3E) . (19) Similar to that seen in the zebrafish mutant, human PFIC2 exhibited hepatocyte swelling and necrosis (red box and inset in Fig. 3D , respectively). At 11 dpf, zebrafish mutant hepatocytes had less defined boundaries compared to WT but no giant cells (Fig. 3B) . Immunofluorescence showed increased laminin deposition in the mutant liver, suggestive of fibrogenic responses (Supporting Fig. S4A-F) . However, the amount of extracellular matrix protein could not be readily detected by sirius red stain (data not shown). Premature death of the mutants prohibited evaluation of advanced fibrosis.
TEM showed that at 5 dpf the hepatocytes in zebrafish mutants had reduced glycogen content and accumulation of amorphous bile-like granular deposits (Fig. 3G, red arrows) . The mitochondria were pleomorphic with irregularities in the arrangement of cristae and often contained electron-dense whorled membranes (compare Fig. 3F,G, red asterisks) . The hepatocyte phenotypes progressively worsened over time. At 2 weeks, mutant hepatocytes no longer had defined cell membranes (Fig. 3I) . The mitochondria were swollen with pale matrix and disintegrating cristae (Fig. 3I, red asterisks) . Similarly, the hepatocytes in patient A exhibited mitochondrial pleomorphism (Fig. 3K, insert) , glycogen depletion, and accumulation of amorphous bile-like granular deposits (Fig. 3K , red arrows). There was modest dilatation of smooth endoplasmic reticulum (ER) and a patchy increase in rough ER (Fig. 3K) . ER stress was also induced in zebrafish mutant livers as revealed by elevated expression of unfolded protein response genes (Supporting Fig.  S4G ). We observed dilatation of the bile canaliculi and effacement of canalicular microvilli in both zebrafish mutants and human PFIC2 (Fig. 3M,O,P) . (19) In zebrafish mutants, bile-like granular deposits were detected in close proximity to the bile canaliculi (Fig.  3O, arrows) , consistent with a failure of bile salt excretion across the canalicular membrane.
Taken together, zebrafish abcb11b mutants recapitulate several common histological and ultrastructural features of human PFIC2 (summarized in Table 1 ).
BILE EXCRETION WAS IMPAIRED IN ABCB11B MUTANT ZEBRAFISH
To evaluate the hepatobiliary function of the abcb11b mutant larvae, we administered fluorescent lipid analog BODIPY C5:0, which consists of a saturated acyl chain of five carbons tagged with the BOD-IPY fluorophore. (13) After being ingested, BODIPY C5:0 is metabolized in the intestine, delivered to the liver, and secreted into bile by hepatocytes. The intrahepatic bile ducts and gallbladder exhibit green fluorescence signal under normal bile flow.
(31) At 6 dpf, 73% of the WT and 77% of the abcb11b heterozygous larvae, but only 11% of the abcb11b mutants, showed green fluorescence signal in the gallbladder (Fig. 4A,B) . Whole-mount immunostaining with the anti-annexin A4 antibody revealed an intact hepatopancreatic ductal system in the mutants (Fig.  4C,D) , (32) suggesting that the lack of BODIPY fluorescence in the mutant gallbladder was not due to malformation of the extrahepatic duct or gallbladder.
To confirm that zebrafish Abcb11b and human BSEP have conserved function, we generated a transgenic construct that expresses a human BSEP-green fluorescent protein fusion protein under the control of the hepatocyte-specific promoter fabp10a. (33) We injected the construct into WT and abcb11b mutant zebrafish at the one-cell stage and detected mosaic expression of the fusion protein in hepatocytes (data not shown). The fusion protein was detected in the canaliculus, colocalized with BSEP antibody staining (Fig. 4E,F) . We raised the injected fish to adulthood. Whereas in the uninjected sibling group only 1 out of 39 adult fish was abcb11b mutant (2.6%), in the injected group 5 out of 44 fish were mutants (11.4%). Next we established stable transgenic fish and performed the BODIPY assay on the larvae: 63% of the transgenic mutants showed positive BODIPY filling in the gallbladder (Fig. 4G) . Thus, expression of human BSEP in the hepatocytes of mutant zebrafish restored bile flow and improved their survival.
To directly examine whether zebrafish Abcb11b is capable of exporting bile acid substrate of human BSEP, we administered fluorescent bile acid derivative CGamF, which has been used as a surrogate for natural cholylglycine to monitor bile acid transport in mammalian hepatocytes. (21) We examined the subcellular distribution of CGamF in the 6-dpf larval livers by confocal live imaging and observed three different patterns (Fig. 4H-J) . In WT and abcb11b heterozygous larvae, CGamF fluorescence was detected throughout the intrahepatic biliary network, the "normal" pattern (Fig. 4H) . The abcb11b mutant larvae had no obvious defect in bile duct morphology (Fig. 2H) , but only few exhibited normal CGamF distribution (Fig. 4K) . Among the mutants, 43% showed the "grade 1" pattern as a CGamF signal was detected only in the large bile duct connecting to the extrahepatic duct (Fig. 4I) . The "grade 2" pattern was shown by 50% of the mutants with no CGamF signal in the intrahepatic biliary network (Fig. 4J) . In the mutant livers, we detected a bright CGamF fluorescence signal close to the bile canaliculi (Fig. 4I,J,  arrowheads) , consistent with the TEM observation (Fig. 3O) . These results confirm the requirement of zebrafish Abcb11b for bile excretion from hepatocytes.
Loss of ABCB11 Caused Mislocalization of MDR1 in Both Human and Zebrafish
In Abcb11 knockout mice, increased expression of MDR1 is thought to compensate for the loss of BSEP, resulting in mild cholestasis. (7) To explore the mechanisms underlying the severe cholestasis seen in abcb11b mutant zebrafish, we examined the expression of abcb4, which is the zebrafish ortholog of human MDR1/ABCB1. (22) Whereas Mdr1 transcript is up-regulated in Abcb11 knockout mice, (7) its expression was not significantly increased in the zebrafish abcb11b mutant livers compared to WT (Fig. 5A ). Mdr1 protein was distributed evenly along the canaliculi in the WT larvae ( Fig. 5B-E) . In abcb11b mutants, Mdr1 protein formed aggregates in the canaliculi (Fig. 5I, arrowheads) . Abundant Mdr1 aggregates were also seen in the cytoplasm of hepatocytes (Fig. 5I, arrows) .
In human, all of the hepatocytes from the control liver expressed MDR1 at the cell membrane (Fig. 5J , 636/636 cells). (34) In patient A, who likely retains some BSEP function based on the mutations, 98% of the hepatocytes, including giant cells, expressed MDR1 at the cell membrane ( Fig. 5K, arrowheads; 145/148 cells). In patient B, with a complete loss of BSEP protein, however, 40% of the hepatocytes expressed MDR1 in the cytoplasm (Fig. 5L, arrows; 105/264 cells). MDR3, another canalicular transporter in the same protein family as BSEP and MDR1, was localized at the cell membrane in 99% of the hepatocytes in the control liver (Fig. 5M, 2769/2771 cells) . In patient B 85% of the hepatocytes still showed The numbers of hepatocytes with mislocalized Mdr1 divided by the total numbers of cells within the liver, including both parenchymal and nonparenchymal cells (mean 6 SEM). Each dot represents the result from an individual liver. Scale bars, (A,B) 2 lm, (C,D) 500 nm, (I-L) 20 lm. Statistical significance in (E,F,M) was calculated by one-way analysis of variance and Tukey's post hoc test, that in (G) was by Fisher's exact test, and that in (H) was by the Ridit test. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Abbreviations: CQ, chloroquine; Het, heterozygote; n, nucleus; ns, nonsignificant; m, mitochondria; Mut, mutant; Rapa, rapamycin. membrane localization of MDR3 (Fig. 5N , arrowheads; 305/355 cells), (10) indicating that the mislocalization of MDR1 seen in patient B was not caused by a universal change in canalicular transporter localization.
Our zebrafish and human data suggest a model that MDR1 is mislocalized in the absence of BSEP and, thus, incapable of playing a compensatory role in bile excretion. This is in contrast to what is proposed for the Abcb11 knockout mice in which MDR1 may compensate for BSEP deficiency. (7) We examined the localization of MDR1 in the knockout mice at 3 months by immunofluorescence and found that MDR1 was localized at the canalicular membrane in the majority of hepatocytes (Fig. 5O,P) . A subcellular fractionation experiment further confirmed that MDR1 was mainly located on the cell membrane in the knockout mice (Fig. 5Q) . Therefore, loss of BSEP has a different impact on MDR1 localization in mouse hepatocytes versus zebrafish and human hepatocytes.
RAPAMYCIN TREATMENT PARTIALLY RESTORED BILE EXCRETION IN ABCB11B MUTANT ZEBRAFISH
Our TEM analyses of the zebrafish abcb11b mutant hepatocytes detected double-membrane microbodies with cytoplasmic materials in the center, resembling autophagic vesicles (Fig. 6B, arrowhead) . The density of these vesicles was significantly higher in the mutants than the WT (Fig. 6E) . Quantitative real-time PCR revealed that expression of autophagic genes was elevated in the mutants compared to the WT (Fig. 6F) , further demonstrating activation of autophagy in the zebrafish abcb11b mutant livers. Autophagic vesicles were also seen in the hepatocytes from patients with PFIC2 (Fig. 6D) .
To investigate the relevance between autophagy and bile excretion defects in abcb11b mutant zebrafish, we treated the fish with the autophagy inhibitor chloroquine. (35) We started the treatment at 3.5 dpf when we first detected Abcb11 protein in the bile canaliculi (36) and stopped at 6 dpf when the mutants showed obvious defects in bile excretion. Chloroquine treatment caused a significant decrease in the percentage of abcb11b heterozygous larvae with positive filling of BODIPY (Fig. 6G) . Thus, inhibition of autophagy perturbed bile flow in the larvae with reduced Abcb11 protein expression. When we treated the larvae with rapamycin, a mammalian target of rapamycin inhibitor known to induce autophagy, there was a significant increase in the percentage of abcb11b mutants with positive gallbladder filling (Fig. 6G) . To further support that activation of autophagy restores bile flow, treatment with 2% trehalose, which induces autophagy by blocking glucose transport and is independent of mammalian target of rapamycin, (37) also improved BODIPY gallbladder filling in the mutants (Supporting Fig. S5 ). To confirm that rapamycin restored canalicular bile salt excretion, we administered CGamF to these animals. In the control group, 75% of the dimethyl sulfoxide (DMSO)-treated mutants showed a grade 2 pattern with no CGamF signal in the intrahepatic bile ducts and none of them had a normal pattern. In contrast, only 44% of the rapamycin-treated mutants showed a grade 2 pattern, and 21% of them even exhibited normal CGamF distribution ( Fig. 6H ; Supporting Fig. S6A,B) . TEM showed that rapamycin treatment rescued the ultrastructural phenotypes of the mutant hepatocytes: the bile canaliculi were less dilated, the microvilli were more densely packed, and bile deposits were no longer evident near the canaliculi (Supporting Fig. S6C-F) . Rapamycin treatment did not cause significant changes in the body length and liver volume (Supporting Fig. S6G,H) . Consistent with the improved liver phenotypes, more mutants survived at 2 weeks of age after continuous rapamycin treatment compared to egg water and DMSO-treated controls (Supporting Table S1 ). We examined the localization of Mdr1 and found that its expression was restored in the canaliculi in abcb11b mutants upon rapamycin treatment (Fig. 6L,M) . These results suggest that rapamycin may prompt other transporters to excrete bile in abcb11b mutants.
Discussion
In this study, we show that in both human and zebrafish loss of Abcb11 is associated with activation of autophagy, impaired bile salt excretion, and retention of amorphous bile-like deposits in hepatocytes. Ultimately, diminished canalicular transport results in severe liver damage. Treating zebrafish abcb11b mutants with rapamycin partially restores bile excretion and prolongs life span. It also correlates with recovery of Mdr1 localization from the cytoplasm to the canaliculi in the mutant hepatocytes. Our study establishes an animal model for studying BSEP deficiency that complements the existing in vitro systems and knockout mouse model. It also suggests that rapamycin may have therapeutic potential by directing alternative transporters to the canaliculus to compensate for BSEP deficiency.
Compensation from MDR1 may account for the mild cholestasis seen in BSEP knockout mice. (7) We show that MDR1 protein is located on the canalicular membrane in these mice. In abcb11b mutant zebrafish, however, Mdr1 is mislocalized to the hepatocyte cytoplasm. Restoration of bile excretion by rapamycin treatment correlates with recovery of canalicular Mdr1 localization in the zebrafish mutant, raising the possibility that Mdr1 may play an evolutionarily conserved role as an alternative bile acid transporter when positioned in the canaliculus. Conducting rapamycin treatment on abcb11b;mdr1 compound mutants will be informative to test this hypothesis. Our data also indicate that MDR1 localization may contribute to the phenotypic heterogeneity in patients with PFIC2: patient A with one truncating and one nontruncating ABCB11 mutation and preserved canalicular MDR1 expression has survived with the native liver beyond 8 years of age, whereas patient B with two truncating mutations and mislocalized MDR1 required liver transplantation in infancy to prolong survival. The correlation between MDR1 localization and disease severity is currently under investigation.
Mislocalization of MDR1 in human PFIC2 is not due to global impairment of hepatocyte polarity or bile canaliculus integrity because canalicular transporters MDR3 and MRP2 are located at the hepatocyte cell membrane in patients with PFIC2. (10) Newly synthesized canalicular transporters are targeted directly from the Golgi to the apical membrane of the hepatocytes. (38) Both MDR3 and MRP2 contain a PDZ domain-binding motif at the C terminus, and their apical localization relies on interactions with other PDZ domain proteins. (39) (40) (41) In contrast, ABCB11 and MDR1 do not contain obvious PDZ domains. Differential regulation of intracellular trafficking may explain why MDR1, but not MDR3 and MRP2, is mislocalized in the absence of ABCB11. In rat hepatocytes ABCB11 and MDR1 are in the same complex at the canalicular membrane. (42, 43) Both ABCB11 and MDR1 recycle between the apical cell membrane and the intracellular vesicles. (38, 44) Thus, it is possible that interaction between ABCB11 and MDR1 is required for their trafficking to the canaliculi.
We discovered that the hepatocytes in abcb11b mutant zebrafish activate autophagy and that treatment with autophagy inducers rapamycin and trehalose restored their bile excretion. We also detected autophagic vesicles in two patients with PFIC2, and more patients should be examined to confirm this observation. Several studies suggest that autophagy could be a treatment target for cholestasis. Augmenting autophagy ameliorates liver injury in mice after bile duct ligation by eliminating accumulation of reactive oxygen species. (45) Autophagic flux is impaired in livers of Fxr knockout mice and in primary mouse hepatocytes treated with bile acids. (46) Increasing bile acid synthesis induces autophagy through the cytochrome P450 7A1-AKT-mammalian target of rapamycin pathway in mice. (47) However, to our knowledge, no previous report has specifically connected autophagy with canalicular bile salt excretion or PFIC2. Autophagy is required for polarization of hepatocytes cultured in a collagen sandwich system. (48) It is plausible that rapamycin increases autophagy and provides more recycled materials to enhance the synthesis of polarized plasma membrane domains, cytoskeleton, and intracellular organelles. This in turn promotes trafficking of other transporters, possibly Mdr1, to the canaliculi to excrete bile. Alternatively, rapamycin may also restore bile excretion through other autophagy-independent mechanisms.
Our work illustrates that abcb11b mutant zebrafish have the potential to reveal novel pathogenic mechanisms and therapeutic strategies for PFIC2. Different from the in vitro systems, abcb11b mutant zebrafish permit studying of BSEP deficiency in living organisms. In human, PFIC2 is early onset and can rapidly progress to end-stage liver disease, with cirrhosis, liver failure, and death commonly occurring in the first year of life. (30) In contrast to Abcb11 knockout mice that survive to adulthood and only develop mild cholestasis, (8) abcb11b mutant zebrafish show severe cholestasis and are premature lethal, similar to what is seen in patients. Zebrafish bile is predominantly composed of bile alcohols, differing from human. (49) However, the substrate spectrum of zebrafish Abcb11b and human ABCB11 may partially overlap as they can both transport CGamF. Furthermore, we show that expressing human BSEP in zebrafish mutant hepatocytes rescues the liver phenotypes and improves mutant survival. These findings signify the relevance of the zebrafish mutants to human PFIC2. The small size of the zebrafish larvae and the ease of tracking liver cells and bile transport in live animals make it an ideal model for whole-organism chemical screens. abcb11b mutants can be applied in high-throughput chemical screens for compounds that restore bile acid excretion and ameliorate hepatobiliary damage. Given the high sequence similarity between human and zebrafish ABCB11 proteins, it will also be interesting to express human ABCB11 mutations in zebrafish to study their biological consequences.
